Cargando…

Cell-based medicinal products approved in the European Union: current evidence and perspectives

Advanced Therapy Medicinal Products (ATMPs) are innovative clinical treatments exploiting the pharmacological, immunological, or metabolic properties of cells and/or gene(s) with the aim to restore, correct, or modify a biological function in the recipient. ATMPs are heterogeneous medicinal products...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellino, Stefania, La Salvia, Anna, Cometa, Maria Francesca, Botta, Rosanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424920/ https://www.ncbi.nlm.nih.gov/pubmed/37583902 http://dx.doi.org/10.3389/fphar.2023.1200808

Ejemplares similares

COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients
por: Bellino, Stefania
Publicado: (2022)

The challenges of access to innovative medicines with limited evidence in the European Union
por: Vallano, Antonio, et al.
Publicado: (2023)

Valorising and Creating Access to Innovative Medicines in the European Union
por: Annemans, Lieven, et al.
Publicado: (2011)

Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013–2017
por: Brown, Jeremy Philip, et al.
Publicado: (2019)

Predictors of orphan drug approval in the European Union
por: Heemstra, Harald E., et al.
Publicado: (2008)

Comparison of the new Japanese legislation for expedited approval of regenerative medicine products with the existing systems in the USA and European Union
por: Jokura, Yoji, et al.
Publicado: (2017)

Approval and Certification of Ophthalmic AI Devices in the European Union
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications
por: Kwon, Hye-Young, et al.
Publicado: (2018)

Engineered Microorganisms for the Production of Food Additives Approved by the European Union—A Systematic Analysis
por: Kallscheuer, Nicolai
Publicado: (2018)

Getting the Right Evidence After Drug Approval
por: Vreman, Rick A., et al.
Publicado: (2020)

A review of patient-reported outcomes used for regulatory approval of oncology medicinal products in the European Union between 2017 and 2020
por: Teixeira, Maria Manuel, et al.
Publicado: (2022)

Single-arm trials supporting the approval of anticancer medicinal products in the European Union: contextualization of trial results and observed clinical benefit
por: Mulder, J., et al.
Publicado: (2023)

Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan
por: Yano, Kazuo, et al.
Publicado: (2014)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Methodological Characteristics of Clinical Trials Supporting the Marketing Authorisation of Advanced Therapies in the European Union
por: Iglesias-Lopez, Carolina, et al.
Publicado: (2021)

Affordability of medicines in the European Union
por: Zaprutko, Tomasz, et al.
Publicado: (2017)

Traditional medicines and globalization: current and future perspectives in ethnopharmacology
por: Leonti, Marco, et al.
Publicado: (2013)

Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries
por: Gozzo, Lucia, et al.
Publicado: (2021)

Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union
por: Pellegrini, Graziella, et al.
Publicado: (2017)

EMEA and Gene Therapy Medicinal Products Development in the European Union
por: Papaluca Amati, Marisa, et al.
Publicado: (2003)

Navigating the maze of requirements for obtaining approval of non-interventional studies (NIS) in the European Union
por: Ramirez, Isabelle
Publicado: (2015)

European Union ban on Ayurvedic Medicines
por: Patwardhan, Bhushan
Publicado: (2011)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Current Prevention of COVID-19: Natural Products and Herbal Medicine
por: Huang, Junqing, et al.
Publicado: (2020)

OMICS Applications for Medicinal Plants in Gastrointestinal Cancers: Current Advancements and Future Perspectives
por: Dai, Rongchen, et al.
Publicado: (2022)

A survey of experts on personalized medicine landscape in European Union and China
por: Hoxhaj, Ilda, et al.
Publicado: (2023)

Composition, Clinical Efficiency, and Mechanism of NHC-Approved “Three Chinese Medicines and Three Chinese Recipes” for COVID-19 Treatment
por: Xia, Ke-Yao, et al.
Publicado: (2022)

Turning Meadow Weeds Into Valuable Species for the Romanian Ethnomedicine While Complying With the Environmentally Friendly Farming Requirements of the European Union’s Common Agricultural Policy
por: Grosu, Elena, et al.
Publicado: (2020)

A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
por: Vella Bonanno, Patricia, et al.
Publicado: (2021)

Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives
por: Ong, Pei Shi, et al.
Publicado: (2016)

Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches
por: Ayoub, Nehad M., et al.
Publicado: (2022)

Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions
por: Yu, Chao-Chao, et al.
Publicado: (2022)

Rethinking the Appraisal and Approval of Drugs for Fracture Prevention
por: Erviti, Juan, et al.
Publicado: (2017)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

The European Medicines Agency's approval of new medicines for type 2 diabetes
por: Blind, Eberhard, et al.
Publicado: (2018)

An overview of Personalized Medicine landscape and policies in the European Union
por: Beccia, F, et al.
Publicado: (2022)

From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds
por: De Sanctis, Rita, et al.
Publicado: (2022)

The Use of Risperidone in Behavioral and Psychological Symptoms of Dementia: A Review of Pharmacology, Clinical Evidence, Regulatory Approvals, and Off-Label Use
por: Yunusa, Ismaeel, et al.
Publicado: (2020)

Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries
por: Pisana, Alice, et al.
Publicado: (2022)

Consumers' acceptance of the first novel insect food approved in the European Union: Predictors of yellow mealworm chips consumption
por: Petrescu‐Mag, Ruxandra Malina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7dvr7v55sc3n2d5prauvffr63p